A multicentre diagnostic accuracy study in Vietnam reports that the urine-based FujiLAM II assay delivers 99.3% specificity but limited sensitivity for pulmonary tuberculosis. The performance profile reflects strong rule-in potential with likely gaps in rule-out use, particularly for patients with lower bacterial loads. The study context matters for clinical workflows: urine testing could improve access in settings where sputum collection is difficult, but the sensitivity limitation could increase missed cases if used as a standalone screening test. For TB programs, the result supports triage strategies that pair urine testing with confirmatory pathways when clinical suspicion remains high. From a development standpoint, it underscores the ongoing need to improve sensitivity for non-sputum specimen tests without compromising specificity.
Get the Daily Brief